144 related articles for article (PubMed ID: 12409074)
1. Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
Piccart MJ; Cardoso F; Atalay G
Eur J Cancer; 2002 Nov; 38 Suppl 6():S52-4. PubMed ID: 12409074
[No Abstract] [Full Text] [Related]
2. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
3. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Smith IE
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
[TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Buzdar AU
J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477
[No Abstract] [Full Text] [Related]
5. Anastrozole versus progestins/tamoxifen.
Beat T
Eur J Cancer; 2002 Nov; 38 Suppl 6():S49-51. PubMed ID: 12409073
[No Abstract] [Full Text] [Related]
6. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Illiger HJ
Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
[No Abstract] [Full Text] [Related]
7. [Endocrine therapy of causation: role of aromatase inhibitors in breast cancer].
Longo F; Mansueto G
Tumori; 2003; 89(6):21-8. PubMed ID: 14870836
[No Abstract] [Full Text] [Related]
8. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
9. Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Twombly R
J Natl Cancer Inst; 2003 Dec; 95(23):1738-9. PubMed ID: 14652229
[No Abstract] [Full Text] [Related]
10. Pre-operative endocrine therapy for postmenopausal women: when and why?
Tondini C; Fenaroli P; Labianca R
Ann Oncol; 2001 Nov; 12(11):1505-6. PubMed ID: 11822746
[No Abstract] [Full Text] [Related]
11. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
12. Breast cancer studies challenge tamoxifen therapy.
Timms B
Lancet Oncol; 2000 Nov; 1():132. PubMed ID: 11905647
[No Abstract] [Full Text] [Related]
13. Letrozole after tamoxifen for breast cancer--what is the price of success?
Bryant J; Wolmark N
N Engl J Med; 2003 Nov; 349(19):1855-7. PubMed ID: 14551339
[No Abstract] [Full Text] [Related]
14. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
15. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
16. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
17. Promising results for Arimidex and Femara.
Expert Rev Anticancer Ther; 2001 Dec; 1(4):508-9. PubMed ID: 12113080
[No Abstract] [Full Text] [Related]
18. [Treatment of metastatic breast carcinoma].
Puglisi F; Sobrero A
Ann Ital Chir; 1999; 70(3):377-89. PubMed ID: 10466241
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Munster PN; Horton J
Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
[No Abstract] [Full Text] [Related]
20. Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Burstein HJ
N Engl J Med; 2003 Nov; 349(19):1857-9. PubMed ID: 14551340
[No Abstract] [Full Text] [Related]
[Next] [New Search]
